Certara vs Frontage Laboratories

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/certara/frontagelab

Category	Certara	Frontage Laboratories
Listed site	cro	cro
Summary	Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.	Global pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
Services	Biostatistics & Statistical Programming Data Management & eClinical Regulatory Affairs Medical Writing Computational & In-Silico Drug Discovery Translational Research Target Identification & Validation High-Throughput Screening Medicinal Chemistry In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Discovery Research In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Preclinical In Vitro Studies Preclinical In Vivo Studies Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Phase I Clinical Trials Biomarker Assays Phase II Clinical Trials Phase III Clinical Trials Clinical Operations Phase IV / Post-Marketing US FDA Regulatory Strategy US FDA Regulatory Strategy EU EMA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy China NMPA Regulatory Strategy Clinical Trial Services	Medicinal Chemistry Computational & In-Silico Drug Discovery In Vitro ADME / DMPK In Vitro Pharmacology Preclinical In Vitro Studies Safety Pharmacology Genetic Toxicology DART (Reproductive & Developmental Toxicology) GLP Toxicology In Vivo PK / PD Studies In Vivo Efficacy Models Preclinical In Vivo Studies Phase I Clinical Trials Phase II Clinical Trials Clinical Operations Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Immunogenicity Assays (ADA / NAb) Biomarker Assays Flow Cytometry Services Central Laboratory Services Pathology & Histology Services Genomics & Sequencing Services Biostatistics & Statistical Programming Data Management & eClinical Medical Writing Analytical Method Development & Validation ICH Stability Studies Discovery Research Target Identification & Validation High-Throughput Screening Specialized & Large-Animal Models Phase III Clinical Trials Clinical Trial Services Regulatory Affairs US FDA Regulatory Strategy
Modalities	Small Molecule Small Molecule Biologics (Monoclonal Antibodies) Biologics (Monoclonal Antibodies) Biologics (Other) Biologics (Other) Peptide Peptide Oligonucleotide Oligonucleotide mRNA mRNA Antibody-Drug Conjugate (ADC) Antibody-Drug Conjugate (ADC) Gene Therapy Gene Therapy Cell Therapy Cell Therapy Vaccine Vaccine	Small Molecule Biologics (Monoclonal Antibodies) Antibody-Drug Conjugate (ADC) Cell Therapy Gene Therapy
Indications	Oncology Rare Disease Immunology Immunology Neurology Neurology Psychiatry Metabolic Metabolic Cardiovascular Cardiovascular Infectious Disease Infectious Disease Respiratory Respiratory Dermatology Dermatology Ophthalmology Ophthalmology Gastroenterology Gastroenterology Nephrology Nephrology Women's Health Women's Health	Oncology
Locations	Global network Global presence, 30 countries Global presence, Multiple, 30 countries, Global Global presence, Multiple, 30+ countries Global presence, Multiple, 30 countries, International Headquarters, Radnor, Pennsylvania, United States Global presence, 30 countries Global presence, 30+ countries	Headquarters Global Operations
Certifications	Data not yet provided.	FDA · Identifier: 200+ FDA Inspections
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.